Syngene expands global footprint with US biologics manufacturing facility acquisition
Syngene International Limited, a leading contract research, development, and manufacturing organization (CRDMO), has acquired its first biologics manufacturing facility in the United States. The newly ... Read More
Emergent BioSolutions introduces next-generation anthrax vaccine
Emergent BioSolutions, a leader in public health preparedness, has introduced a cutting-edge anthrax vaccine aimed at enhancing global readiness against biological threats. This development marks ... Read More
Hikma Pharmaceuticals partners with Emergent BioSolutions to expand access to KLOXXADO nasal spray
Hikma Pharmaceuticals PLC has announced an exclusive partnership with Emergent BioSolutions to commercialise KLOXXADO (naloxone HCl) nasal spray 8 mg in the United States and ... Read More
Emergent BioSolutions’ ACAM2000 receives FDA approval for Mpox prevention
Emergent BioSolutions Inc. (NYSE: EBS) has achieved a notable milestone with the U.S. Food and Drug Administration (FDA) approving the supplemental Biologics License Application (sBLA) ... Read More
Emergent’s Narcan nasal spray receives OTC nod for opioid overdose treatment
Emergent BioSolutions’ Narcan nasal spray has secured over-the-counter (OTC) designation from the US Food and Drug Administration (FDA), becoming the first and only prescription strength ... Read More
Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions
Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to $380 million, to strengthen its position in ... Read More
Emergent BioSolutions begins phase 3 trial of CHIKV VLP vaccine candidate
Emergent BioSolutions said that it has dosed the first participant in a phase 3 clinical trial of CHIKV VLP — the company’s single-dose chikungunya vaccine ... Read More